TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Monday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD opened at $1.72 on Monday. The business’s 50-day moving average price is $1.76 and its 200 day moving average price is $1.96. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $3.35.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.23 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Prosperity Consulting Group LLC acquired a new stake in TherapeuticsMD during the 1st quarter worth about $56,000. Clearline Capital LP lifted its position in shares of TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after purchasing an additional 101,282 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth approximately $612,000. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.